Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.

Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL.

Sci Transl Med. 2012 Sep 26;4(153):153ra131.

3.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
4.

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.

De Felice B, Mondola P, Sasso A, Orefice G, Bresciamorra V, Vacca G, Biffali E, Borra M, Pannone R.

BMC Med Genomics. 2014 May 17;7:26. doi: 10.1186/1755-8794-7-26.

5.

Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.

Mahurkar S, Suppiah V, O'Doherty C.

Autoimmun Rev. 2014 Feb;13(2):178-86. doi: 10.1016/j.autrev.2013.10.012. Epub 2013 Nov 2. Review. Erratum in: Autoimmun Rev. 2014 Dec;13(12):1243.

PMID:
24189284
6.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

7.

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.

Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ.

J Neuroimmunol. 2004 Jul;152(1-2):126-39.

PMID:
15223245
8.

Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.

Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL.

J Neuroimmunol. 2011 Apr;233(1-2):168-74. doi: 10.1016/j.jneuroim.2010.10.038. Epub 2010 Nov 27.

PMID:
21115201
9.

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO.

Pharmacogenomics. 2014 Apr;15(5):679-85. doi: 10.2217/pgs.14.26.

PMID:
24798724
10.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
11.

Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A.

PLoS One. 2014 Jul 15;9(7):e102331. doi: 10.1371/journal.pone.0102331. eCollection 2014.

12.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
13.

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.

Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.

Adv Ther. 2008 Jul;25(7):658-73. doi: 10.1007/s12325-008-0077-z. Erratum in: Adv Ther. 2008 Aug;25(8):830. Oleen-Burkey, Merry-Kay A [corrected to Oleen-Burkey, MerriKay].

PMID:
18641926
14.

Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.

Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, Tenaglia S, Di Filippo M, Calabresi P.

Mult Scler. 2007 Apr;13(3):313-31. Epub 2007 Jan 29.

PMID:
17439900
16.

Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.

Putheti P, Pettersson A, Soderstrom M, Link H, Huang YM.

J Clin Immunol. 2004 Mar;24(2):155-61.

PMID:
15024182
17.

Glatiramer acetate (Copaxone).

Francis DA.

Int J Clin Pract. 2001 Jul-Aug;55(6):394-8. Review.

PMID:
11501229
18.

Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.

Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS.

Mult Scler. 2013 Feb;19(2):179-87. doi: 10.1177/1352458512450353. Epub 2012 May 31.

PMID:
22653658
19.

Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Hecker M, Hartmann C, Kandulski O, Paap BK, Koczan D, Thiesen HJ, Zettl UK.

Mol Neurobiol. 2013 Dec;48(3):737-56. doi: 10.1007/s12035-013-8463-1. Epub 2013 May 1.

PMID:
23636981
20.

Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.

Kennedy P.

J Neurosci Nurs. 2013 Dec;45(6 Suppl 1):S3-13. doi: 10.1097/JNN.0000000000000021. Review.

PMID:
24217189

Supplemental Content

Support Center